Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BenraliScan: CT Air-trapping Characterisation for Early Identification of Benralizumab Responders in Eosinophilic Asthma
NCT03976310Completed
- Sponsor
- CHU Montpellier
- Start
- Jun 2019
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by CHU Montpellier. Primary endpoints: Prognostic value (sensitivity) of baseline expiratory to inspiratory mean lung density at 52 weeks and Prognostic value (specificity) of baseline expiratory to inspiratory mean lung density at 52 weeks. Started Jun 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03976310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976310.